VHL: A Rare Disease with Potential Drug Targets (G7428)

Target Name: VHL

NCBI ID: G7428

Content of Review Report on VHL Target / Biomarker

VHL

VHL: A Rare Disease with Potential Drug Targets

VHL (Von Willebrand disease) is a rare autosomal recessive bleeding disorder that is caused by a deficiency of the protein G7. G7 is a transmembrane protein that is involved in the regulation of cell adhesion and signaling. It is composed of two chains, A and B, that are held together by a disulfide bond.

The protein G7 is expressed in many tissues throughout the body, including the blood vessels, neurons, and epithelial cells. It is involved in the formation of blood clots, which are essential for maintaining blood pressure and preventing blood from leaking into the surrounding tissue. In addition, G7 is involved in the regulation of cell signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival.

Studies have suggested that VHL may be a drug target or biomarker for a variety of diseases. For example, G7 has been shown to be involved in the regulation of platelet function, which is important for blood clotting. Therefore, drugs that can modulate platelet function may be effective in treating bleeding disorders such as VHL. In addition, G7 has been shown to be involved in the regulation of cell signaling pathways, which may make it a useful biomarker for some types of cancer.

One of the challenges in studying VHL is the fact that it is a rare disease, and there are few research groups that specialize in it. In addition, the molecular mechanisms underlying VHL are not well understood, which can make it difficult to design effective treatments. However, research into the protein G7 is ongoing, and there is hope that it will lead to new treatments for VHL and other rare diseases.

Protein Name: Von Hippel-Lindau Tumor Suppressor

Functions: Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases. Ubiquitinates, in an oxygen-responsive manner, ADRB2

The "VHL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VHL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets